Successful Retreatment of Glecaprevir‐Pibrentasvir for Hepatitis C Virus Genotype 2a Infection in Patient Whose Cirrhosis Improved From Decompensation to Compensation After Sofosbuvir–Velpatasvir Therapy

Hepatology ResearchEarly View LETTER TO THE EDITOR Successful Retreatment of Glecaprevir-Pibrentasvir for Hepatitis C Virus Genotype 2a Infection in Patient Whose Cirrhosis Improved From Decompensation to Compensation After Sofosbuvir–Velpatasvir Therapy This article relates to: Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Norifumi Kawada, Akio Ido, Daiki Miki, Masayuki Kurosaki, Hitoshi Yoshiji, Ryotaro Sakamori, Hidekatsu Kuroda, Hiroshi Yatsuhashi, Taro Yamashita, Yoichi Hiasa, Naoya Kato, Hisamitsu Miyaaki, Yoshiyuki Ueno, Yoshito Itoh, Kentaro Matsuura, Taro Takami, Yasuhiro Asahina, Goki Suda, Norio Akuta, Ryosuke Tateishi, Yasunari Nakamoto, Eiji Kakazu, Shuji Terai, Masahito Shimizu, Masanori Miyazaki, Yasutoshi Nozaki, Satoshi Sobue, Hiroki Yano, Tomokatsu Miyaki, Akihiro Moriuchi, Takeshi Hori, Kumiko Shirai, Kazuhiro Murai, Yoshinobu Saito, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara, Volume 55Issue 3Hepatology Research pages: 319-332 First Published online: October 29, 2024 Tatsuo Kanda, Corresponding Author Tatsuo Kanda [email protected] orcid.org/0009-0000-8135-342X Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan Division of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan Correspondence: Tatsuo Kanda ([email protected])Search for more papers by this authorRyota Masuzaki, Ryota Masuzaki orcid.org/0000-0001-5118-4397 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, JapanSearch for more papers by this authorNaoki Matsumoto, Naoki Matsumoto orcid.org/0000-0002-9982-6130 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, JapanSearch for more papers by this authorReina Sasaki-Tanaka, Reina Sasaki-Tanaka orcid.org/0000-0003-2681-0776 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Chuo-ku, JapanSearch for more papers by this authorHirofumi Kogure, Hirofumi Kogure orcid.org/0000-0002-2355-7309 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, JapanSearch for more papers by this author Tatsuo Kanda, Corresponding Author Tatsuo Kanda [email protected] orcid.org/0009-0000-8135-342X Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan Division of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan Correspondence: Tatsuo Kanda ([email protected])Search for more papers by this authorRyota Masuzaki, Ryota Masuzaki orcid.org/0000-0001-5118-4397 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, JapanSearch for more papers by this authorNaoki Matsumoto, Naoki Matsumoto orcid.org/0000-0002-9982-6130 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, JapanSearch for more papers by this authorReina Sasaki-Tanaka, Reina Sasaki-Tanaka orcid.org/0000-0003-2681-0776 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Chuo-ku, JapanSearch for more papers by this authorHirofumi Kogure, Hirofumi Kogure orcid.org/0000-0002-2355-7309 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, JapanSearch for more papers by this author First published: 27 September 2025 https://doi.org/10.1111/hepr.70046 Funding: The authors received no specific funding for this work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookxLinkedInRedditWechatBluesky No abstract is available for this article. References 1Y. Tahata, H. Hikita, S. Mochida, et al., "Factors Involved in Gastroesophageal Varix-Related Events in Patients With Hepatitis C Virus-Related Compensated and Decompensated Cirrhosis After Direct-Acting Antiviral Therapy," Hepatology Research 55, no. 3 (October 29, 2024): 319–332, https://doi.org/10.1111/hepr.14131. 10.1111/hepr.14131 Web of Science® Google Scholar 2 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology, "Japan Society of Hepatology Guidelines for the Management of Hepatitis C Virus Infection: 2019 Update," Hepatology Research 50, no. 7 (2020): 791–816, https://doi.org/10.1111/hepr.13503. 10.1111/hepr.13503 PubMed Web of Science® Google Scholar 3C. González-Corvillo, I. Beneyto, A. Sánchez-Fructuoso, et al., "Direct-Acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-Term Prospective Observational Study," Transplant Direct 5, no. 12 (2019): e510, https://doi.org/10.1097/TXD.0000000000000954. 10.1097/TXD.0000000000000954 CAS PubMed Google Scholar 4R. de Franchis, J. Bosch, G. Garcia-Tsao, T. Reiberger, C. Ripoll, and Baveno VII Faculty, "Baveno VII - Renewing Consensus in Portal Hypertension," Journal of Hepatology 76, no. 4 (2022): 959–974, https://doi.org/10.1016/j.jhep.2021.12.022. 10.1016/j.jhep.2021.12.022 PubMed Web of Science® Google Scholar 5Y. Shiratori, Y. Ito, O. Yokosuka, et al., "Antiviral Therapy for Cirrhotic Hepatitis C: Association With Reduced Hepatocellular Carcinoma Development and Improved Survival," Annals of Internal Medicine 142, no. 2 (2005): 105–114, https://doi.org/10.7326/0003-4819-142-2-200501180-00009. 10.7326/0003-4819-142-2-200501180-00009 CAS PubMed Web of Science® Google Scholar 6O. El-Sherif, Z. G. Jiang, E. B. Tapper, et al., "Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection," Gastroenterology 154, no. 8 (2018): 2111–2121.e8, https://doi.org/10.1053/j.gastro.2018.03.022. 10.1053/j.gastro.2018.03.022 CAS PubMed Web of Science® Google Scholar 7T. Takehara, N. Sakamoto, S. Nishiguchi, et al., "Efficacy and Safety of Sofosbuvir-Velpatasvir With or Without Ribavirin in HCV-Infected Japanese Patients With Decompensated Cirrhosis: An Open-Label Phase 3 Trial," Journal of Gastroenterology 54, no. 1 (2019): 87–95, https://doi.org/10.1007/s00535-018-1503-x. 10.1007/s00535-018-1503-x CAS PubMed Web of Science® Google Scholar 8M. Atsukawa, A. Tsubota, C. Kondo, et al., "Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients With Genotype 1 and 2: A Prospective, Multicenter Study," Infectious Disease and Therapy 9, no. 4 (2020): 851–866, https://doi.org/10.1007/s40121-020-00329-y. 10.1007/s40121-020-00329-y PubMed Web of Science® Google Scholar 9Y. Tahata, H. Hikita, S. Mochida, et al., "Posttreatment Liver Function, But Not Baseline Liver Function Stratifies Patient Survival After Direct-Acting Antiviral Treatment in Decompensated Cirrhosis With Hepatitis C Virus," Journal of Gastroenterology 58, no. 12 (2023): 1211–1221, https://doi.org/10.1007/s00535-023-02039-x. 10.1007/s00535-023-02039-x PubMed Web of Science® Google Scholar 10S. Ramirez, C. Fernandez-Antunez, L. S. Mikkelsen, J. Pedersen, Y. P. Li, and J. Bukh, "Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir Against Hepatitis C Virus Genotypes 2a, 2b, and 2c," Antimicrobial Agents and Chemotherapy 64, no. 3 (2020): e01888-19, https://doi.org/10.1128/AAC.01888-19. 10.1128/AAC.01888-19 PubMed Web of Science® Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation